Summary & Overview

CPT 0438U: EffectiveRX™ Pharmacogenomic Panel, 33 Genes

CPT code 0438U represents a Proprietary Laboratory Analyses (PLA) test — the EffectiveRX™ Comprehensive Panel from RCA Laboratory Services LLC, d/b/a GENETWORx — that performs variant analysis of 33 genes and CYP2D6 duplication/deletion testing from a buccal swab to produce patient-specific drug–response phenotypes and gene–drug interaction information. Such pharmacogenomic panels are increasingly used to inform medication selection and dosing and can influence prescribing practices at a national level.

Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations and common payer practices, benchmark indicators for lab-based molecular diagnostics, and clinical context on how pharmacogenomic test results are applied to personalized medication planning. The publication also summarizes coding details, typical sites of service, and available data elements. Data not available in the input include associated taxonomies, specific ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0438UCPTproprietary laboratory analysespharmacogenomicsgenetic testingmolecular diagnosticbuccal swabCYP2D6personalized medicine

Billing Code Overview

CPT code 0438U is a Proprietary Laboratory Analyses (PLA) code that describes the EffectiveRX™ Comprehensive Panel produced by RCA Laboratory Services LLC, d/b/a GENETWORx. The test analyzes genetic variants across 33 genes and includes duplication/deletion evaluation for the CYP2D6 gene using a buccal (cheek) swab specimen. Results are used to generate a personalized treatment plan that reports patient drug–response phenotypes and gene–drug interactions based on established clinical drug data.

Service type: Genetic pharmacogenomic testing / molecular diagnostic assay

Typical site of service: Outpatient laboratory or clinician office where buccal swab specimens are collected, with laboratory processing performed by the proprietary lab.

Clinical & Coding Specifications

Clinical Context

A 45-year-old patient with a history of multiple medication trials for major depressive disorder and persistent treatment-emergent adverse effects is referred by a primary care physician to a psychiatric clinic for pharmacogenomic testing. The clinician orders the EffectiveRX™ Comprehensive Panel (0438U) from GENETWORx to assess single nucleotide variants across 33 pharmacogenes and CYP2D6 copy-number variation using a buccal swab. The patient provides informed consent, completes a buccal swab collection at the clinic, and the specimen is forwarded to the laboratory. The lab performs variant analysis and duplication/deletion testing for CYP2D6, interprets results relative to established drug–gene interaction databases, and returns a report that includes patient drug–response phenotypes and a personalized medication guidance summary. The clinician reviews the report with the patient to inform medication selection and dosing adjustments, documents the test result in the electronic medical record, and communicates changes to the prescribing providers and pharmacy as needed.

Coding Specifications

Modifier	Description	When to Use
`00`	Procedure code without modifier	Rarely used; default when no modifier applies

Taxonomy Code	Specialty	Notes
`207Q00000X`	Clinical Laboratory Geneticist	Providers responsible for test interpretation and reporting
`2084P0800X`	Clinical Pathology	Laboratories performing molecular diagnostic testing and oversight
`2085R0200X`	Medical Biochemical Genetics	Specialists applying results to pharmacogenomic interpretation
`208000000X`	Family Medicine	Ordering providers who commonly request pharmacogenomic testing for medication management
`208000000X`	Psychiatry	Ordering providers managing psychotropic medication selection and dosing

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F32.9`	Major depressive disorder, single episode, unspecified	Common indication for pharmacogenomic testing to guide antidepressant selection and dosing
`F33.1`	Major depressive disorder, recurrent, moderate	Used when multiple treatment trials have failed and pharmacogenomic data may inform medication changes
`F41.1`	Generalized anxiety disorder	Pharmacogenomic testing can guide medication choices for anxiety when multiple agents are considered
`G43.909`	Migraine, unspecified, not intractable, without status migrainosus	Some patients with migraine require medication tailoring where pharmacogenomics informs therapy
`I10`	Essential (primary) hypertension	Pharmacogenomic variants can affect response to antihypertensive agents and guide therapy selection

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81225`	CYP2D6 gene analysis, common variants and copy number (example)	May be ordered when targeted CYP2D6 testing is required or to confirm copy-number findings; overlaps with duplication/deletion evaluation reported in `0438U`
`81226`	CYP2C19 gene analysis	Often complementary when broader pharmacogenomic profiling is performed for antiplatelet or psychotropic drug metabolism
`81479`	Unlisted molecular pathology procedure	Used when a proprietary PLA test lacks an applicable CPT and reporting is required for unusual or additional analyses (less common for PLA-coded tests)
`99000`	Handling and/or conveyance of specimen for transfer from patient to laboratory (example)	Administrative or courier charges sometimes billed separately when specimens are shipped to external labs
`G0452`	Specimen handling for molecular pathology (example)	Used in certain payer contexts for specimen handling; may accompany laboratory billing workflows